金融界5月28日消息，上证指数高开震荡，上证中小国企改革指数 (中小企改，950080)报2416.30点。 数据统计显示，上证中小国企改革指数近一个月上涨1.38%，近三个月下跌0.69%，年至今下跌3.49%。 据了解，上证中小国企改革指数优选已被中央和地方国资委列为国企改革试点、或已出台相关重大资产 重组方案、或已出台相关国企改革方案、或已完成国企改革的沪市国企上市公司证券作为指数样本，以 反映沪市中小国企改革主题上市公司证券的整体表现。该指数以2013年12月31日为基日，以1000.0点为 基点。 从指数持仓来看，上证中小国企改革指数十大权重分别为：申能股份（3.24%）、西部超导 （3.21%）、物产中大（3.21%）、华域汽车（3.18%）、扬农化工（3.06%）、天坛生物（3.01%）、沪 硅产业（3.01%）、国睿科技（2.98%）、老白干酒（2.91%）、中直股份（2.82%）。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3月、6月、9月和12月的第二个星 期五的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在 下一个定期调整日前，权重 ...

Core Viewpoint - The global semiconductor industry is showing signs of recovery, but the recovery of semiconductor wafer production is lagging behind the overall market, with several A-share semiconductor wafer companies experiencing profit declines in Q1 2025 [1] Group 1: Market Trends - The semiconductor wafer industry entered a cyclical inventory adjustment phase since Q4 2022, with global wafer shipments expected to decline to 12.266 billion square inches in 2024, a year-on-year decrease of 2.67%, and sales expected to drop to $11.5 billion, a decline of 6.5% [2] - In Q1 2024, the semiconductor wafer market maintained a mild recovery, with global wafer shipment area increasing by 4.6% year-on-year, although there was a divergence in different sizes: 300mm wafer shipments grew by 5.7%, while 200mm shipments declined by 2.9% [2] Group 2: Company Performance - Shanghai Silicon Industry reported a revenue of approximately 3.388 billion yuan last year, with a net profit loss of about 971 million yuan, and a net profit loss of around 200 million yuan in Q1 this year [2] - Li Wei, the executive vice president of Shanghai Silicon Industry, indicated that sales and overall revenue are expected to rise in 2024 and Q1 2025, but price recovery depends on further market recovery [2] - Lian Microelectronics reported a revenue of 3.092 billion yuan last year, a year-on-year increase of nearly 15%, but a net profit loss of 266 million yuan due to cost pressures from capacity expansion and product price declines [3] Group 3: Capacity Expansion - The focus of capacity expansion is shifting towards 12-inch semiconductor wafers, with Lian Microelectronics' factories in Jiaxing and Quzhou currently in the ramp-up phase [4] - Lian Microelectronics plans to invest 1.23 billion yuan in a project to produce 960,000 pieces of 12-inch epitaxial wafers annually [4] - Shanghai Silicon Industry's 12-inch wafer capacity is expected to reach 600,000 pieces per month by the end of 2024, with ongoing capacity construction in Taiyuan [5] Group 4: Capital Operations - Semiconductor wafer companies are actively engaging in capital operations, with Shanghai Silicon Industry planning to acquire minority stakes in subsidiaries for 7.04 billion yuan to enhance its 300mm wafer business [6] - Yuyuan Silicon is expanding through acquisitions, including a plan to acquire 60% of High Frequency (Beijing) Technology Co., a supplier of ultra-pure water systems for chip manufacturing [7] - Yuyuan Silicon also plans to acquire 70% of DG Technologies for 11.91 billion yen, which will help enhance its manufacturing technology for etching equipment [7]

我是芯片超人花姐，入行20年，有50W+芯片行业粉丝。 有很多不方便公开发公众号的， 关于芯片买卖、关于资源链接等， 我会分享在朋友圈 。 扫码加我本人微信 一周大 事件 行业风向前瞻 商务部：支持国家级经开区集成电路、生物医药、高端装备制造等领域的外商投资项目优先纳入重大和重点外资项目清单 商务部印发《深化国家级经济技术开发区改革创新以高水平开放引领高质量发展工作方案》。支持国家级经开区集成电路、生物医药、高端装备制造 等领域的外商投资项目优先纳入重大和重点外资项目清单。地方人民政府加大对国家级经开区外资标志性项目的支持力度，推动尽快落地建设。鼓励 包括外资基金在内的各类资金投向国家级经开区新兴产业领域，培育孵化中小企业。指导国家级经开区落实好境外投资者以分配利润再投资递延纳税 等税收优惠政策。（财联社） 美国芯片四巨头呼吁特朗普政府免除半导体关税 特朗普政府有意征收半导体芯片关税，继台积电呼吁勿开征相关关税后，美国半导体四巨头 英特尔、高通、美光、德州仪器 也出具意见书同声呼吁 「免除半导体进口税负」，否则将冲击美国半导体产业能量。（集微网） 1、 美国芯片四巨头呼吁特朗普政府免除半导体关税 2、 中科曙 ...

Core Viewpoint - The semiconductor market is showing signs of recovery, with expectations for increased shipment volumes and prices for silicon wafers, driven by normalizing inventory levels among downstream customers [2] Group 1: Company Performance - In 2024, the company reported a revenue of 3.388 billion yuan and a net loss attributable to shareholders of 971 million yuan; for Q1 2025, the revenue was 802 million yuan with a net loss of 209 million yuan [2] - The company has experienced rapid growth in domestic sales, with limited overseas revenue, resulting in minimal impact from tariff policies on overall sales [2] Group 2: Industry Outlook - The global semiconductor market is undergoing a recovery trend following industry adjustments, but the recovery of silicon wafers is lagging behind the overall market due to a longer transmission cycle from downstream to upstream [2] - The company anticipates an upward trend in sales volume and overall revenue for 2024 and Q1 2025, although price recovery is contingent on further market improvements [2] Group 3: Capacity Expansion and Capital Operations - By the end of 2024, the company's Shanghai plant is expected to achieve a capacity of 600,000 12-inch wafers per month, meeting its construction goals; the Taiyuan plant is also progressing with a capacity of 50,000 wafers per month [3] - The company is pursuing a capital operation plan to acquire minority stakes in several entities for a total of approximately 7.04 billion yuan, which will enhance management integration and resource optimization for its 300mm silicon wafer projects [3]

金融界5月23日消息，上证指数低开低走，中证万得重组主题指数 (CSWD重组，930640)下跌1.17%，报 1567.53点，成交额404.53亿元。 数据统计显示，中证万得重组主题指数近一个月上涨3.77%，近三个月下跌4.89%，年至今下跌5.54%。 从中证万得重组主题指数持仓的市场板块来看，深圳证券交易所占比57.05%、上海证券交易所占比 42.66%、北京证券交易所占比0.29%。 从中证万得重组主题指数持仓样本的行业来看，信息技术占比30.18%、工业占比28.50%、可选消费占 比9.86%、金融占比7.69%、原材料占比7.41%、通信服务占比6.02%、主要消费占比3.31%、房地产占比 2.36%、医药卫生占比2.18%、公用事业占比1.98%、能源占比0.50%。 资料显示，指数样本每月调整一次，样本调整实施时间为每月第一个交易日。权重因子随样本定期调整 而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不 变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、 合并、分拆等情形的处理，参照计算与维护细则处理。 ...

| 府号 | 交易对方 | 交易标的名称 及权益比例 | 支付方式 现金对价 | 股份对价 | 可转债 | 其他 | 同该交易对方支 付总对价 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 对价 | | | | 1 | 避雷非受体 | 新昇晶投 | 174.265.107.35 | 1.568.385.966.19 | 元 | 元 | 1.742.651.073.54 | | | 基金 | 43.9863%股权 | | | | | | | 2 | 晶融投资 | 新昇晶投 | 108.915.692.10 | | 元 | 元 | 108.915.692.10 | | | | 2.7491%股权 | | | | | | | ਤੇ | 产业基金 | 新昇晶科 | | 3.407.017.543.86 | 元 | 元 | 3.407.017.543.86 | | | 二期 | 43.8596%股权 | | | | | | | র্ব | 上海闪芯 | 新异晶科 | 40,884,210.53 | 367.957.894.74 | 元 | ...

Core Viewpoint - Hu Silicon Industry (688126.SH) is planning a major asset restructuring by acquiring minority stakes in three subsidiaries for a total consideration of approximately 7.04 billion yuan, aiming for full control over these companies [1][2]. Group 1: Acquisition Details - The total transaction price is approximately 7.04 billion yuan, with 6.716 billion yuan paid through share issuance and 324 million yuan in cash [2]. - The company plans to raise up to 2.105 billion yuan through a private placement to specific investors, with a proposed share price of 15.01 yuan per share, representing about 14.01% of the total share capital post-transaction [2][3]. - After the transaction, the National Integrated Circuit Industry Investment Fund II will hold 299 million shares, accounting for 9.36% of the total shares [3]. Group 2: Business Context - The three target companies are involved in the 300mm silicon wafer project, with a focus on cutting, grinding, and pulling related to semiconductor wafers [3]. - The domestic market for 300mm silicon wafers is currently dominated by international leaders, and there is a significant gap in the supply of high-end silicon wafers domestically [3][5]. - The acquisition is aimed at accelerating the domestic production of 300mm silicon wafers to meet the rapidly growing demand from core domestic customers [3][5]. Group 3: Financial Performance - All three target companies are currently operating at a loss, and Hu Silicon Industry itself is projected to incur significant losses in 2024, with a net profit of -971 million yuan, a decline of 620.28% year-on-year [4][6]. - The company reported revenues of approximately 3.388 billion yuan in 2024, a 6.18% increase year-on-year, but the net profit has significantly decreased due to various market pressures [6][7]. - The semiconductor industry is experiencing a downturn, leading to reduced capital expenditures from wafer manufacturers, which affects the pricing and demand for silicon wafers [7][8]. Group 4: Market Outlook - The global market for semiconductor wafers is expected to grow from 8.7 billion USD in 2017 to 11.5 billion USD by 2024, with a compound annual growth rate of 4.07% [4]. - The demand for high-end semiconductor wafers is increasing due to domestic policy support and technological advancements, prompting companies to enhance their R&D investments [5].

Core Viewpoint - The company, Hu Silicon Industry, is planning a significant acquisition of approximately 7.04 billion yuan to purchase minority stakes in three subsidiaries, which are currently operating at a loss. This acquisition is expected to impact the company's financial performance negatively in the short term [1][5]. Group 1: Acquisition Details - The acquisition involves purchasing stakes in Shanghai Xinsheng Crystal Semiconductor Technology Co., Ltd., Shanghai Xinsheng Crystal Science and Technology Co., Ltd., and Shanghai Xinsheng Crystal Rui Semiconductor Technology Co., Ltd. The total transaction price is approximately 70.40 billion yuan, with 3.24 billion yuan in cash and 67.16 billion yuan in shares [2][3]. - The targeted subsidiaries have reported continuous losses, with projected net losses of 46.21 million yuan, 89.91 million yuan, and 28.71 million yuan for the year 2024, totaling around 165 million yuan [4]. Group 2: Financial Performance - The company reported a net loss of 9.71 billion yuan for 2024, a significant decline of 620.28% year-on-year, primarily due to lower sales and average prices of semiconductor wafers [8]. - In the first quarter of the current year, the company experienced a net loss of 2.09 billion yuan, continuing the trend of financial underperformance [8][9]. - Cumulatively, the company has reported a total net loss of 11.80 billion yuan for 2024 and the first quarter of the current year [9]. Group 3: Market Position and Strategy - Hu Silicon Industry is a leading player in the semiconductor wafer industry, focusing on expanding production capacity and optimizing product offerings to maintain its competitive edge [6][4]. - The company has been actively investing in expanding its production capabilities, including a planned investment of 13.2 billion yuan to increase the production scale of 300mm wafers [6].

Core Viewpoint - Shanghai Silicon Industry Group Co., Ltd. (referred to as "the company") plans to acquire minority stakes in three semiconductor companies, aiming to enhance resource integration and competitiveness in the semiconductor silicon wafer market [1][2]. Group 1: Acquisition Details - The company intends to purchase minority stakes in Shanghai Xinxing Crystal Technology Co., Ltd. (referred to as "Xinxing Crystal"), Shanghai Xinxing Crystal Semiconductor Technology Co., Ltd. (referred to as "Xinxing Semiconductor"), and Shanghai Xinxing Crystal Smart Technology Co., Ltd. (referred to as "Xinxing Smart") through a combination of share issuance and cash payment, with a total acquisition price of approximately 7.04 billion yuan [1]. - Following the transaction, the company will hold 100% equity in the three target companies, with no change in control or actual controller before and after the transaction [1]. Group 2: Industry Context - The semiconductor industry is experiencing rapid growth, driven by increasing demand from end markets such as smartphones and computers, as well as emerging fields like artificial intelligence and automotive electronics [3]. - The demand for semiconductor silicon wafers is supported by product upgrades and technological advancements, expanding the market space for the industry [3]. - The target companies primarily engage in the production of 300mm semiconductor silicon wafers, aligning with the company's existing business and enhancing its competitive position in the market [2].

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]